OVERVIEW

Cartalax 20 mg (Bioregulator) is a short synthetic peptide composed of the amino acid sequence alanine–glutamic acid–aspartic acid (AED) that has been studied in laboratory and preclinical research for its bioregulatory effects on connective tissues and cellular aging processes. Research indicates that Cartalax can influence fibroblast function — the cells responsible for producing collagen and other extracellular matrix components — by increasing cell proliferation, decreasing markers of programmed cell death, and modulating signaling pathways such as NF‑κB and p53 that are involved in inflammation and senescence. These cellular actions have made it of interest in experimental models of skin health, connective tissue maintenance, and age‑related cellular changes, with some research suggesting potential support for tissue regeneration, extracellular matrix remodeling, and improved cell vitality.

Despite these research findings, Cartalax 20 mg is not approved by major regulatory bodies such as the U.S. Food and Drug Administration for therapeutic use in humans and remains classified as a research compound. It is typically supplied as a lyophilized peptide for laboratory investigation only, meaning its purity, quality, and effects in humans are not established and may vary between sources. While some preclinical data and theoretical models suggest potential benefits in cartilage, joints, and aging tissues, robust clinical evidence in humans is lacking. Therefore, Cartalax should be used exclusively in controlled research settings by qualified professionals, and individuals should consult healthcare professionals rather than self‑administer unapproved peptides.